Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5037175 | 0.83 | ELANE (0.35) | ELANESMN1; SMN2HCRTR1TP53MAPT | |
| SCHEMBL6529295 | 0.83 | ELANE (0.35) | ELANESMN1; SMN2HCRTR1TP53MAPT | |
| SCHEMBL7107773 | 0.83 | ELANE (0.35) | ELANESMN1; SMN2HCRTR1TP53MAPT | |
| SCHEMBL5840166 | 0.78 | NTRK1 (0.32) | ELANE | |
| SCHEMBL5839892 | 0.78 | NTRK1 (0.32) | ELANE | |
| SCHEMBL5840220 | 0.78 | ELANE (0.32) | ELANE | |
| SCHEMBL4967094 | 0.77 | ELANE (0.32) | ELANE | |
| SCHEMBL4967104 | 0.77 | ELANE (0.32) | ELANE | |
| SCHEMBL5839762 | 0.77 | ELANE (0.32) | ELANE | |
| SCHEMBL6031960 | 0.77 | ATP4A (0.33) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414821-B1 | TRICYCLIC EPOXIDES | ALTANA PHARMA AG (DE) | 2006-08-16 | — | — | EP | disclosed |
| US-6927292-B2 | Tricyclic epoxides | ALTANA PHARMA AG (DE) | 2005-08-09 | — | — | US | disclosed |
| US-20040176597-A1 | Tricyclic epoxides | ALTANA PHARMA AG (DE) | 2004-09-09 | — | — | US | disclosed |
| EP-1414821-A1 | TRICYCLIC EPOXIDES | ALTANA Pharma AG (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003014119-A1 | TRICYCLIC EPOXIDES | ALTANA PHARMA AG (DE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176597-A1 | Tricyclic epoxides | VKORC1, CYP2E1, CYP1A2 | ELANE 327/4885SMN1; SMN2 4216/4885HCRTR1 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.